对Chwal等人的评论。糖尿病且无高心血管疾病风险的成年人中，目标低密度脂蛋白胆固醇水平与更高死亡率相关，独立于早期死亡或虚弱因素。2024年，，7667。
Comment on Chwal et al. On-Target Low-Density Lipoprotein Cholesterol in Adults with Diabetes Not at High Cardiovascular Disease Risk Predicts Greater Mortality, Independent of Early Deaths or Frailty. 2024, , 7667.
作者信息
van Bruggen Folkert H, Luijendijk Hendrika J
机构信息
Department of Primary and Long-Term Care, University Medical Centre Groningen, University of Groningen, P.O. Box 196, 9700 AD Groningen, The Netherlands.
出版信息
J Clin Med. 2025 Apr 8;14(8):2559. doi: 10.3390/jcm14082559.
Abstract
The ELSA-Brasil study provides important insights into the association between LDL-C levels and all-cause mortality in adults with diabetes who are not at high cardiovascular risk [...].
摘要
ELSA-Brasil研究为无高心血管疾病风险的糖尿病成年患者中低密度脂蛋白胆固醇（LDL-C）水平与全因死亡率之间的关联提供了重要见解。
相似文献
1
Comment on Chwal et al. On-Target Low-Density Lipoprotein Cholesterol in Adults with Diabetes Not at High Cardiovascular Disease Risk Predicts Greater Mortality, Independent of Early Deaths or Frailty. 2024, , 7667.对Chwal等人的评论。糖尿病且无高心血管疾病风险的成年人中，目标低密度脂蛋白胆固醇水平与更高死亡率相关，独立于早期死亡或虚弱因素。2024年，，7667。
J Clin Med. 2025 Apr 8;14(8):2559. doi: 10.3390/jcm14082559.
2
Reply to van Bruggen, F.H.; Luijendijk, H.J. Comment on "Chwal et al. On-Target Low-Density Lipoprotein Cholesterol in Adults with Diabetes Not at High Cardiovascular Disease Risk Predicts Greater Mortality, Independent of Early Deaths or Frailty. 2024, , 7667".回复范·布鲁根，F.H.；路易金迪克，H.J. 对“Chwal等人。糖尿病且无高心血管疾病风险的成年人中，目标低密度脂蛋白胆固醇水平预测更高死亡率，独立于早期死亡或虚弱因素。2024年，，7667”的评论。
J Clin Med. 2025 Apr 21;14(8):2845. doi: 10.3390/jcm14082845.
3
On-Target Low-Density Lipoprotein Cholesterol in Adults with Diabetes Not at High Cardiovascular Disease Risk Predicts Greater Mortality, Independent of Early Deaths or Frailty.在无高心血管疾病风险的糖尿病成人患者中，达到目标值的低密度脂蛋白胆固醇水平可预测更高的死亡率，且独立于早期死亡或虚弱因素。
J Clin Med. 2024 Dec 16;13(24):7667. doi: 10.3390/jcm13247667.
4
Association of Low-Density Lipoprotein Cholesterol Levels with More than 20-Year Risk of Cardiovascular and All-Cause Mortality in the General Population.低密度脂蛋白胆固醇水平与普通人群 20 多年心血管和全因死亡率的关系。
J Am Heart Assoc. 2022 Aug 2;11(15):e023690. doi: 10.1161/JAHA.121.023690. Epub 2022 Jul 29.
5
A Prospective Study to Evaluate the Possible Role of Cholecalciferol Supplementation on Autoimmunity in Hashimoto's Thyroiditis.一项评估胆钙化醇补充对桥本甲状腺炎自身免疫可能作用的前瞻性研究。
J Assoc Physicians India. 2023 Jan;71(1):1.
6
The predictive study of the relation between elevated low-density lipoprotein cholesterol to high-density lipoprotein cholesterol ratio and mortality in peritoneal dialysis.低密度脂蛋白胆固醇与高密度脂蛋白胆固醇比值升高与腹膜透析患者死亡率的预测研究。
Lipids Health Dis. 2020 Mar 21;19(1):51. doi: 10.1186/s12944-020-01240-8.
7
Achievement of Treatment Goals and Mortality in Individuals with Diabetes: The ELSA-Brasil Study.糖尿病患者治疗目标的达成与死亡率：巴西动脉粥样硬化多民族研究（ELSA-Brasil研究）
J Clin Med. 2023 Dec 13;12(24):7663. doi: 10.3390/jcm12247663.
8
Association between lipoprotein cholesterol and future cardiovascular disease and mortality in older adults: a Korean nationwide longitudinal study.脂蛋白胆固醇与老年人未来心血管疾病和死亡率的关系：一项韩国全国性纵向研究。
Lipids Health Dis. 2021 Jan 6;20(1):3. doi: 10.1186/s12944-020-01426-0.
9
The prevalence and correlates of subclinical atherosclerosis among adults with low-density lipoprotein cholesterol <70 mg/dL: The Multi-Ethnic Study of Atherosclerosis (MESA) and Brazilian Longitudinal Study of Adult Health (ELSA-Brasil).在低密度脂蛋白胆固醇<70mg/dL的成年人中，亚临床动脉粥样硬化的流行率及相关因素：动脉粥样硬化多民族研究（MESA）和巴西成人健康纵向研究（ELSA-Brasil）。
Atherosclerosis. 2018 Jul;274:61-66. doi: 10.1016/j.atherosclerosis.2018.04.021. Epub 2018 Apr 28.
10
Association of triglyceride-glucose index, low and high-density lipoprotein cholesterol with all-cause and cardiovascular disease mortality in generally Chinese elderly: a retrospective cohort study.甘油三酯-葡萄糖指数、高低密度脂蛋白胆固醇与中国一般老年人全因和心血管疾病死亡率的关系：一项回顾性队列研究。
Front Endocrinol (Lausanne). 2024 Oct 29;15:1422086. doi: 10.3389/fendo.2024.1422086. eCollection 2024.
引用本文的文献
1
A global prediction of cardiovascular disease from 2020 to 2030.2020年至2030年心血管疾病的全球预测。
Front Cardiovasc Med. 2025 Aug 11;12:1462705. doi: 10.3389/fcvm.2025.1462705. eCollection 2025.
2
Is Targeting LDL-C Levels Below 70 mg/dL Beneficial for Cardiovascular and Overall Health? A Critical Examination of the Evidence.将低密度脂蛋白胆固醇（LDL-C）水平降至70mg/dL以下对心血管和整体健康有益吗？对证据的批判性审视。
J Clin Med. 2025 May 20;14(10):3569. doi: 10.3390/jcm14103569.
本文引用的文献
1
On-Target Low-Density Lipoprotein Cholesterol in Adults with Diabetes Not at High Cardiovascular Disease Risk Predicts Greater Mortality, Independent of Early Deaths or Frailty.在无高心血管疾病风险的糖尿病成人患者中，达到目标值的低密度脂蛋白胆固醇水平可预测更高的死亡率，且独立于早期死亡或虚弱因素。
J Clin Med. 2024 Dec 16;13(24):7667. doi: 10.3390/jcm13247667.
2
Contribution of infection to mortality in people with type 2 diabetes: a population-based cohort study using electronic records.感染对2型糖尿病患者死亡率的影响：一项基于人群的队列研究，采用电子记录数据
Lancet Reg Health Eur. 2024 Nov 27;48:101147. doi: 10.1016/j.lanepe.2024.101147. eCollection 2025 Jan.
3
Evolocumab's Long-Term Mortality Risk Unclear Due to Shortened Follow-Up of FOURIER.由于 FOURIER 的随访时间缩短，依洛尤单抗的长期死亡率仍不明确。
Am J Cardiovasc Drugs. 2022 Jan;22(1):5-8. doi: 10.1007/s40256-021-00480-y. Epub 2021 May 19.
4
Diabetes, Glycemic Control, and Risk of Infection Morbidity and Mortality: A Cohort Study.糖尿病、血糖控制与感染性发病和死亡风险：一项队列研究。
Open Forum Infect Dis. 2019 Aug 16;6(10):ofz358. doi: 10.1093/ofid/ofz358. eCollection 2019 Oct.
5
Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial.在伴有或不伴有糖尿病的急性冠脉综合征患者中，阿利西尤单抗对心血管和代谢结局的影响：ODYSSEY OUTCOMES 随机对照试验的预先指定分析。
Lancet Diabetes Endocrinol. 2019 Aug;7(8):618-628. doi: 10.1016/S2213-8587(19)30158-5. Epub 2019 Jul 1.
6
Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trial.在有和没有糖尿病的患者中，PCSK9 抑制剂依洛尤单抗的心血管安全性和疗效，以及依洛尤单抗对血糖和新发糖尿病风险的影响： FOURIER 随机对照试验的预先指定分析。
Lancet Diabetes Endocrinol. 2017 Dec;5(12):941-950. doi: 10.1016/S2213-8587(17)30313-3. Epub 2017 Sep 15.
Zotero 插件